Thera-SAbDab

CAROTUXIMAB

>   Structural Summary
TherapeuticCarotuximab
TargetENG
Heavy ChainEVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS
Light ChainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Phase-II
Estimated Status (October '21)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedNational Cancer Institute (USA), Santen Pharmaceutical, TRACON Pharmaceuticals, University of Alabama at Birmingham, University of Minnesota, Roswell Park Cancer Institute
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedFallopian tube cancer, Ovarian cancer, Peritoneal cancer, Prostate cancer, Haemangiosarcoma, Choriocarcinoma, Glioblastoma, Liver cancer, Renal cell carcinoma, Soft tissue sarcoma, Breast cancer, Non-small cell lung cancer, Acute myeloid leukaemia, Colorectal cancer, Precursor B-cell lymphoblastic leukaemia-lymphoma, Wet age-related macular degeneration
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy